Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) – Research analysts at Oppenheimer Holdings issued their Q1 2018 earnings per share (EPS) estimates for Vanda Pharmaceuticals in a research note issued on Monday. Oppenheimer Holdings analyst D. Archila expects that the biopharmaceutical company will post earnings of ($0.15) per share for the quarter. Oppenheimer Holdings has a “Buy” rating and a $21.00 price objective on the stock. Oppenheimer Holdings also issued estimates for Vanda Pharmaceuticals’ Q2 2018 earnings at ($0.07) EPS, FY2018 earnings at ($0.10) EPS, FY2019 earnings at $0.29 EPS and FY2020 earnings at $0.72 EPS.

Vanda Pharmaceuticals (NASDAQ:VNDA) last announced its quarterly earnings data on Wednesday, August 2nd. The biopharmaceutical company reported ($0.03) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.21) by $0.18. Vanda Pharmaceuticals had a negative net margin of 6.54% and a negative return on equity of 7.85%. The company had revenue of $42.06 million during the quarter, compared to analysts’ expectations of $40.31 million. During the same quarter in the prior year, the company earned $0.01 EPS. The firm’s revenue was up 16.7% on a year-over-year basis.

WARNING: “Oppenheimer Holdings Comments on Vanda Pharmaceuticals Inc.’s Q1 2018 Earnings (VNDA)” was first reported by American Banking News and is the sole property of of American Banking News. If you are viewing this news story on another site, it was illegally copied and reposted in violation of United States & international copyright legislation. The correct version of this news story can be viewed at https://www.americanbankingnews.com/2017/10/12/oppenheimer-holdings-comments-on-vanda-pharmaceuticals-inc-s-q1-2018-earnings-vnda.html.

Several other research firms have also commented on VNDA. Piper Jaffray Companies reaffirmed an “overweight” rating and set a $23.00 price objective on shares of Vanda Pharmaceuticals in a research note on Tuesday, June 27th. Jefferies Group LLC reaffirmed a “buy” rating and set a $21.00 price objective on shares of Vanda Pharmaceuticals in a research note on Tuesday, August 29th. Zacks Investment Research lowered shares of Vanda Pharmaceuticals from a “hold” rating to a “strong sell” rating in a research note on Tuesday, July 18th. HC Wainwright set a $18.00 price objective on shares of Vanda Pharmaceuticals and gave the stock a “buy” rating in a research note on Thursday, August 3rd. Finally, BidaskClub raised shares of Vanda Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Tuesday, August 22nd. One investment analyst has rated the stock with a sell rating, one has given a hold rating and six have assigned a buy rating to the stock. Vanda Pharmaceuticals currently has an average rating of “Buy” and a consensus price target of $21.29.

Institutional investors and hedge funds have recently modified their holdings of the company. Legal & General Group Plc boosted its stake in shares of Vanda Pharmaceuticals by 37.4% during the second quarter. Legal & General Group Plc now owns 11,105 shares of the biopharmaceutical company’s stock valued at $181,000 after purchasing an additional 3,022 shares during the period. Kopp Investment Advisors LLC purchased a new stake in shares of Vanda Pharmaceuticals during the second quarter valued at $196,000. Virginia Retirement Systems ET AL purchased a new stake in shares of Vanda Pharmaceuticals during the first quarter valued at $193,000. Dynamic Technology Lab Private Ltd purchased a new stake in shares of Vanda Pharmaceuticals during the first quarter valued at $196,000. Finally, Voya Investment Management LLC boosted its stake in shares of Vanda Pharmaceuticals by 29.7% during the second quarter. Voya Investment Management LLC now owns 20,118 shares of the biopharmaceutical company’s stock valued at $328,000 after purchasing an additional 4,605 shares during the period. 86.49% of the stock is owned by hedge funds and other institutional investors.

About Vanda Pharmaceuticals

Vanda Pharmaceuticals Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapies to address unmet medical needs. Its product portfolio includes HETLIOZ (tasimelteon), Fanapt (iloperidone), Tradipitant (VLY-686), Trichostatin A and AQW051. It offers HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24).

Earnings History and Estimates for Vanda Pharmaceuticals (NASDAQ:VNDA)

Receive News & Ratings for Vanda Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vanda Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.